Non-metastatic castrate-sensitive prostate cancer (nmCSPC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Uveal melanoma (UM) is the most common primary intraocular cancer in adults, with over 8,000 new cases reported annually throughout the world. With a grim prognosis, up to 50% of patients with advanced UM develop metastatic disease, frequently via a hematogenous pathway in the liver. The most common type of intraocular cancer is uveal melanoma (UM), which arises from melanocytes in the iris, ciliary body, or choroid. Early diagnosis and local treatment are crucial because survival is correlated with the size of the primary tumor. Despite the inherent differences between these molecularly different conditions, dacarbazine, a chemotherapeutic option for treating cutaneous melanoma, has been used for uveal melanoma, but activity has been limited.

Description

The term nonmetastatic castration-resistant prostate cancer (nmCRPC) refers to castrate levels of testosterone despite continued androgen restriction therapy or orchiectomy, growing prostate-specific antigen concentrations, and the absence of identifiable metastases by standard imaging. Patients with nmCRPC who acquire metastatic disease run the risk of experiencing cancer-related symptoms and morbidity as well as passing away from their condition. Although most nmCRPC patients have no symptoms, they are frequently elderly and have chronic comorbidities that necessitate long-term concurrent therapy. The benefit-risk profile of proposed treatments must therefore be carefully considered. Castration-resistant prostate cancer (CRPC) is defined by a castrate serum testosterone level of 50 ng/dL in conjunction with biochemical or radiological progression. Metastases detected by conventional imaging with computerized tomography (CT) or technetium-99m scintigraphy in patients with CRPC are classified as metastatic castration-resistant prostate cancer (mCRPC), while CRPC without radiographic evidence of metastases is classified as nonmetastatic CRPC (nmCRPC). The most widely accepted definition of nmCRPC is a 25% increase from the PSA nadir (considering an initial value of 1 ng/mL) in men with castrate levels of serum testosterone, with a minimum rise of 2 ng/mL, which must be confirmed with a second value obtained 1-3 weeks later without evidence of metastases.

Non-metastatic castrate-sensitive prostate cancer (nmCSPC) (Epidemiology)

One in every five cancer diagnoses in men is prostate cancer, making it the most common type of cancer in this group. Men in the US die from cancer-related causes more frequently from metastatic prostate cancer than any other type. Prostate cancer cases began to decline in 2000, and since the U.S. S. The Preventive Services Task Force modified the S. recommendations for PSA (prostate-specific antigen) screening in 2008 and 2011. Over the same time period, there has been an increase in the incidence of metastatic prostate cancer in the US; according to at least one study, there was a 72% increase in mCSPC cases in 2013 compared to 2004. Although it is unknown whether the increase in mCSPC is specifically related to changes in screening guidelines, this increase is concerning because mCSPC is typically thought to be incurable. The 5-year survival rate for locally advanced prostate cancer is 100%, but for metastatic castration-resistant prostate cancer, it is only 29%.

Non-metastatic castrate-sensitive prostate cancer (nmCSPC) -Current Market Size & Forecast Trends

The market for non-metastatic castrate-sensitive prostate cancer (nmCSPC) is projected to grow significantly, with estimates indicating a value of approximately USD 7.68 billion in 2024, expected to reach around USD 14.13 billion by 2037, reflecting a compound annual growth rate (CAGR) of over 4.8% during the forecast period. This growth is driven by the increasing prevalence of prostate cancer, particularly among the aging population, as well as advancements in treatment options and rising awareness of early diagnosis and management. North America is anticipated to dominate the market, accounting for a substantial share due to high healthcare expenditure and ongoing clinical trials. Additionally, Europe is expected to hold a significant share owing to its strong drug development landscape and high incidence rates of prostate cancer. Overall, the nmCSPC market is well-positioned for steady growth through 2035, supported by innovative therapies and increased investment in cancer research.

Patients with metastatic castration-resistant prostate cancer (mCRPC) were the first to benefit from enzalutamide's effectiveness as an androgen receptor inhibitor. Recent studies have demonstrated the clinical benefit of using enzalutamide prior to the onset of metastatic castration-sensitive prostate cancer (mCRPC), such as in metastatic castration-sensitive prostate cancer (mCSPC) and non-mCSPC. Further research is needed on the subpopulation of men who have elevated PSA but no sign of metastatic disease on standard imaging (CT/MRI and Tc99 bone scan). After definitive surgery or radiation therapy but before PSA risers, this subpopulation develops. The mainstay of treatment for advanced prostate cancer since the 1940s has been androgen-deprivation therapy (ADT). It typically results in disease regression, which is typically demonstrated by drops in PSA, improved radiographic results, and clinical improvement. Patients with a PSA-only recurrence and a good prognosis will be chosen to receive salvage prostate bed radiation therapy (RT) in addition to ADT to achieve long-term biochemical control and lengthen cancer-specific survival after radical prostatectomy. Traditionally, first-generation AR inhibitors, corticosteroids, ketocobalamin, or a combination of these drugs are added to or removed from the treatment regimen for M0CRPC. Observation is also done using PSA-DT and imaging studies. Oncologic Drugs Advisory Committee (ODAC) meeting in 2011 discussed the ideal trial design and suitable clinical trial endpoints for drug development in M0CRPC. Second-generation anti-androgens are currently thought to be the gold standard of care for treating M0CRPC. Apalutamide and enzalutamide were ultimately FDA approved for M0CRPC in 2018 on the basis of comparable phase III trials showing noticeably longer MFS compared to placebo. The FDA recently approved darolutamide as the third oral agent, following ARAMIS, which also demonstrated MFS improvement in the AR inhibitor arm of a phase III randomized controlled trial comparing darolutamide to placebo in men with M0CRPC.

Report Highlights

Non-metastatic castrate-sensitive prostate cancer (nmCSPC) - Current Market Trends

Non-metastatic castrate-sensitive prostate cancer (nmCSPC) - Current & Forecasted Cases across the G8 Countries

Non-metastatic castrate-sensitive prostate cancer (nmCSPC) - Market Opportunities and Sales Potential for Agents

Non-metastatic castrate-sensitive prostate cancer (nmCSPC) - Patient-based Market Forecast to 2035

Non-metastatic castrate-sensitive prostate cancer (nmCSPC) - Untapped Business Opportunities

Non-metastatic castrate-sensitive prostate cancer (nmCSPC) - Product Positioning Vis-a-vis Competitors' Products

Non-metastatic castrate-sensitive prostate cancer (nmCSPC) - KOLs Insight